Neil W. Gibson

7.5k citations

86 papers · 5.2k indexed · 2 hit papers · h-index 34

Molecular Biology top 2%
Oncology top 1%
Pulmonary and Respiratory Medicine top 2%
Cancer Research top 2%
Organic Chemistry top 2%

Co-authors: David Ross John D. Haley Elizabeth Buck David Siegel Kenneth K. Iwata Stuart Thomson Filippo Petti Graeme Griffin
Topics: Cancer therapeutics and mechanisms (23 papers)Bioactive Compounds and Antitumor Agents (15 papers)Synthesis and Biological Evaluation (11 papers)
Cited by: Toxicology Oncology Cancer Research
Journals: Journal of Biological Chemistry PLoS ONE Biochemistry
Partner nations: United States United Kingdom Canada

In The Last Decade

Neil W. Gibson

86 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition

2005 525 citations Stuart Thomson, Elizabeth Buck et al. Cancer Research profile →
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

1987 335 citations Neil W. Gibson et al. profile →

Peers

Countries citing papers authored by Neil W. Gibson

Since Specialization

Citations

This map shows the geographic impact of Neil W. Gibson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil W. Gibson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil W. Gibson more than expected).

Fields of papers citing papers by Neil W. Gibson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil W. Gibson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil W. Gibson. The network helps show where Neil W. Gibson may publish in the future.

Co-authorship network of co-authors of Neil W. Gibson

This figure shows the co-authorship network connecting the top 25 collaborators of Neil W. Gibson. A scholar is included among the top collaborators of Neil W. Gibson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil W. Gibson. Neil W. Gibson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NOTCH1 Signaling Promotes Human T-Cell Acute Lymphoblastic Leukemia Initiating Cell Regeneration in Supportive Niches 2012 ·PLoS ONE ·Wenxue Ma,Alejandro Gutiérrez,Daniel Goff,Ifat Geron,Anil Sadarangani,Christina Jamieson,Angela C. Court,Alice Shih,Qingfei Jiang,Christina Wu,Kang Li,Kristen M. Smith,Leslie Crews,Neil W. Gibson,Ida Deichaite,Sheldon Morris,Ping Wei,Dennis A. Carson,A. Thomas Look,(unknown),(unknown)	29
2	Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin 2011 ·Molecular Cancer Therapeutics ·Shripad V. Bhagwat,Prafulla C. Gokhale,Andrew P. Crew,(unknown),Yan Yao,Christine Mantis,Jennifer Kahler,(unknown),Mark Bittner,Lorina Dudkin,David Epstein,Neil W. Gibson,Robert Wild,Lee D. Arnold,Peter J. Houghton,Jonathan A. Pachter	159
3	Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors 2008 ·Cancer Research ·Elizabeth Buck,Alexandra Eyzaguirre,Maryland Rosenfeld-Franklin,Stuart Thomson,Mark J. Mulvihill,Sharon Barr,Eric Brown,(unknown),Yan Yao,Jonathan A. Pachter,Mark Miglarese,David Epstein,Kenneth K. Iwata,John D. Haley,Neil W. Gibson,Qunsheng Ji	164
4	Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions 2008 ·Clinical & Experimental Metastasis ·Sharon Barr,Stuart Thomson,Elizabeth Buck,Suzanne Russo,Filippo Petti,(unknown),Alexandra Eyzaguirre,Maryland Rosenfeld-Franklin,Neil W. Gibson,Mark Miglarese,David Epstein,Kenneth K. Iwata,John D. Haley	169
5	A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo 2007 ·Molecular Cancer Therapeutics ·Qunsheng Ji,Mark J. Mulvihill,Maryland Rosenfeld-Franklin,Andrew Cooke,Lixin Feng,(unknown),Matthew O’Connor,Yan Yao,Caroline Pirritt,Elizabeth Buck,Alexandra Eyzaguirre,Lee D. Arnold,Neil W. Gibson,Jonathan A. Pachter	118
6	Inhibition of IGF-1R by OSI-906 potentiates efficacy of various molecular targeted agents by blocking feedback loops converging at the level of IRS-1 2007 ·Molecular Cancer Therapeutics ·Elizabeth Buck,Alexandra Eyzaguirre,Maryland Rosenfeld-Franklin,Sharon Barr,Jonathan A. Pachter,Kenneth K. Iwata,John D. Haley,Neil W. Gibson,Qunsheng Ji	1
7	Preclinical characterization of OSI-906: A novel IGF-1R kinase inhibitor in clinical trials 2007 ·Molecular Cancer Therapeutics ·Qunsheng Ji,Mark J. Mulvihill,Maryland Rosenfeld-Franklin,Elizabeth Buck,Andrew Cooke,Alexandra Eyzaguirre,(unknown),Matthew O’Connor,Caroline Pirritt,Yan Yao,Neil W. Gibson,Jonathan A. Pachter	4
8	Phosphotyrosine Signaling Networks in Epidermal Growth Factor Receptor Overexpressing Squamous Carcinoma Cells 2005 ·Molecular & Cellular Proteomics ·(unknown),Filippo Petti,Graeme Griffin,Ken Iwata,(unknown),(unknown),David Fenyö,Neil W. Gibson,John D. Haley	119
9	Role of NAD(P)H:Quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin 1996 ·Biochemical Pharmacology ·Howard D. Beall,Yafei Liu,David Siegel,(unknown),Neil W. Gibson,David Ross	62
10	Reactive Oxygen Species and DNA Damage in 2-Bromo-(glutathione-S-yl) hydroquinone-Mediated Cytotoxicity 1995 ·Archives of Biochemistry and Biophysics ·(unknown),Neil W. Gibson,S S Lau,Terrence J. Monks	40
11	Molecular dynamics simulations provide A structural basis for the experimentally observed nucleotide preferences for DNA interstrand cross-links induced by aziridinylbenzoquinones 1993 ·Biochemistry ·Ian S. Haworth,Chong Soon Lee,(unknown),Neil W. Gibson	5
12	DNA interstrand cross-links induced by the cyclopropylpyrroloindole antitumor agent bizelesin are reversible upon exposure to alkali 1993 ·Biochemistry ·(unknown),Neil W. Gibson	22
13	Nucleotide preferences for DNA interstrand cross-linking induced by the cyclopropylpyrroloindole analog U-77,779 1993 ·Biochemistry ·(unknown),Neil W. Gibson	21
14	DT-diaphorase in activation and detoxification of quinones 1993 ·Cancer and Metastasis Reviews ·David Ross,David Siegel,Howard D. Beall,A. S. Prakash,Ríona Mulcahy,Neil W. Gibson	166
15	Bioreductive activation of mitomycin C by DT-diaphorase 1992 ·Biochemistry ·David Siegel,Howard D. Beall,(unknown),Masaji Kasai,Hitoshi Arai,Neil W. Gibson,David Ross	137
16	Alteration in DNA cross-linking and sequence selectivity of a series of aziridinylbenzoquinones after enzymic reduction by DT-diaphorase 1992 ·Biochemistry ·(unknown),J.A. Hartley,Mark Berardini,John Butler,David Siegel,David Ross,Neil W. Gibson	45
17	Effect of methylated forms of selenium on cell viability and the induction of DNA strand breakage 1992 ·Biochemical Pharmacology ·Adrian C. Wilson,Henry J. Thompson,Pepper Schedin,Neil W. Gibson,Howard E. Ganther	64
18	A note on the inhibition of DT-diaphorase by dicoumarol 1991 ·Free Radical Biology and Medicine ·Peter C. Preusch,David Siegel,Neil W. Gibson,David Ross	67
19	DNA crosslinking and sequence selectivity of aziridinylbenzoquinones: a unique reaction at 5'-GC-3' sequences with 2,5-diaziridinyl-1,4-benzoquinone upon reduction 1991 ·Biochemistry ·J.A. Hartley,Mark Berardini,Mauro Ponti,Neil W. Gibson,Andrew S. Thompson,David E. Thurston,Brigid M. Hoey,John Butler	33
20	A comparative study of the anti-tumour activity of N-methylformamide and related compounds. 1981 ·British Journal of Cancer ·(unknown),Neil W. Gibson,John A. Hickman,Andreas J. Gescher,Malcolm F. G. Stevens	1

About Neil W. Gibson

Neil W. Gibson is a scholar working on Toxicology, Organic Chemistry and Cancer Research, having authored 86 papers that have together received 5.2k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (23 papers), Bioactive Compounds and Antitumor Agents (15 papers) and Synthesis and Biological Evaluation (11 papers). The work is most often cited by research in Toxicology (773 citations), Oncology (1.7k citations) and Cancer Research (832 citations). Neil W. Gibson has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include David Ross, John D. Haley, Elizabeth Buck, David Siegel, Kenneth K. Iwata, Stuart Thomson, Filippo Petti, Graeme Griffin, Eric Brown and Alexandra Eyzaguirre. Their work appears in journals such as Journal of Biological Chemistry, PLoS ONE and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact